PRESS RELEASE: Australian Company Announces Landmark Paper Showing Cyclodextrin Therapy Reverses Heart Disease, Hailed as “Greatest Development Since Statins”

GOLD COAST, QUEENSLAND – August 18, 2025 – Cholrem Pty Ltd, an Australian pharmaceutical research company, today announced the publication of a landmark scientific paper providing compelling clinical evidence that its proprietary cyclodextrin based therapy can induce rapid symptomatic relief and objective regression of atherosclerotic cardiovascular disease (ASCVD), the world’s leading cause of death.
The paper, a case series published in the peer-reviewed journal Cardiology Research and Cardiovascular Medicine, documents the outcomes of high-risk patients treated with Cavadex, a formulation of 2-hydroxypropyl-β-cyclodextrin (HPβCD). The findings represent a potential paradigm shift in the treatment of heart disease, moving beyond current therapies that merely slow disease progression to a new approach that actively reverses the underlying pathology of arterial plaque.

The clinical evidence presented is striking. In a documented subset of 20 patients with advanced, symptomatic angina, 18 (90%) reported significant clinical improvement—a rate that is highly statistically significant (P<0.0001) compared to expected spontaneous improvement. This subjective relief was corroborated by objective imaging data, including unprecedented reversals in Coronary Artery Calcium (CAC) scores (e.g., a reduction from 591 to 521) and angiographic evidence of reduced arterial narrowing, such as a 70% blockage in a critical coronary artery being reduced to just 27%. The late Professor Laurie G. Howes, a co-author of the paper and a pre-eminent Australian cardiologist with over 40 years of experience, concluded after reviewing the data that the therapy "may represent the greatest pharmacological development in cardiology since the introduction of statins." He noted that it "removes cholesterol from diseased arteries at a rate much faster than can be achieved by any other method currently available." The development of Cavadex has been championed by the Australian company Cholrem, founded by Kyle Hodgetts, a patient with recurrent heart disease who was failed by conventional treatments, discovered the preclinical research on cyclodextrin and became the first human to trial it for this purpose. Cholrem is pioneering this therapy in the face of a pharmaceutical industry that has largely overlooked the non-patentable molecule. Because HPβCD has been used safely for decades as a drug delivery vehicle and cannot be patented for a new use, it has failed to attract the large-scale investment typical for blockbuster drugs, despite its enormous therapeutic potential. Dr. James C. Roberts, a U.S. board-certified invasive cardiologist and co-author of the paper who has treated hundreds of patients with the therapy, described the benefits as "remarkable." He stated, "We are seeing rapid and profound symptomatic improvement in our highest-risk patients, corroborated by objective data showing plaque regression. The therapy is exceptionally well-tolerated, leveraging a molecule that has an established safety profile with both TGA and FDA approval for other uses. It works by stimulating the body's natural vascular repair program." The paper concludes that while the findings are preliminary, their consistency and magnitude provide a clear and urgent mandate for the initiation of large-scale, randomized controlled trials. Cholrem and its network of clinical collaborators are calling on the global medical community to validate these findings for the benefit of the millions of people suffering from heart disease worldwide. About Cholrem Pty Ltd: Cholrem Pty Ltd is an Australian pharmaceutical research company dedicated to advancing cyclodextrin-based therapies for the treatment of atherosclerotic cardiovascular disease. Founded by Kyle Hodgetts, the company is committed to developing and providing access to innovative treatments that have the potential to reverse the world's number one killer. Over the past four years, Cholrem has supplied over 20,000 units of its product to patients globally. Media Contact: Kyle Hodgetts, Founder & CEO Cholrem Pty Ltd [email protected]